Alkermes (NASDAQ:ALKS) Issues FY 2026 Earnings Guidance

05 May 2026, 08:49 by Scott Moore · The Cerbat Gem

Alkermes (NASDAQ:ALKS – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of -0.521–0.405 for the period, compared to the consensus EPS estimate of -0.090. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ALKS. HC Wainwright restated a “neutral” rating and issued a $43.00 price target on shares of Alkermes in a report on Thursday, February 26th. Piper Sandler lowered their price target on Alkermes from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Tuesday, March 24th. Wall Street Zen downgraded Alkermes from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Bank of America increased their price target on Alkermes from $34.00 to $36.00 and gave the stock a “neutral” rating in a report on Thursday, April 9th. Finally, Wolfe Research began coverage on Alkermes in a report on Monday, February 23rd. They set an “outperform” rating and a $45.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.29.

Get Our Latest Stock Analysis on ALKS

Alkermes Stock Performance

NASDAQ:ALKS opened at $34.17 on Tuesday. The stock has a 50-day simple moving average of $31.44 and a 200 day simple moving average of $30.95. Alkermes has a 52-week low of $25.17 and a 52-week high of $36.48. The company has a market cap of $5.68 billion, a PE ratio of 23.90 and a beta of 0.31.

Alkermes (NASDAQ:ALKS – Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported $0.29 EPS for the quarter. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The firm had revenue of $384.55 million during the quarter. On average, research analysts predict that Alkermes will post -0.69 earnings per share for the current fiscal year.

Insider Activity at Alkermes

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $33.40, for a total transaction of $300,600.00. Following the completion of the transaction, the executive vice president directly owned 81,389 shares of the company’s stock, valued at approximately $2,718,392.60. This represents a 9.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Joseph Gaffin sold 2,034 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.20, for a total value of $67,528.80. Following the transaction, the executive vice president directly owned 231,558 shares of the company’s stock, valued at $7,687,725.60. This trade represents a 0.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 39,102 shares of company stock valued at $1,265,090. Insiders own 4.59% of the company’s stock.

Institutional Trading of Alkermes

A number of hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Alkermes in the fourth quarter valued at approximately $59,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Alkermes in the fourth quarter valued at approximately $256,000. Summit Global Investments lifted its position in shares of Alkermes by 48.8% in the fourth quarter. Summit Global Investments now owns 29,662 shares of the company’s stock valued at $830,000 after buying an additional 9,724 shares during the last quarter. Vident Advisory LLC lifted its position in shares of Alkermes by 1.1% in the fourth quarter. Vident Advisory LLC now owns 82,294 shares of the company’s stock valued at $2,303,000 after buying an additional 864 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Alkermes in the fourth quarter valued at approximately $1,712,000. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Company Profile

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.